Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

被引：114

作者：

Amin, Asim

Plimack, Elizabeth R.

Infante, Jeffrey R.

Ernstoff, Marc S.

Rini, Brian I.

McDermott, David F.

Knox, Jennifer J.

Pal, Sumanta Kumar

Voss, Martin Henner

Sharma, Padmanee

Kollmannsberger, Christian K.

Heng, Daniel Yick Chin

Spratlin, Jennifer L.

Shen, Yun

Kurland, John F.

Gagnier, Paul

Hammers, Hans J.

机构：

[1] Levine Canc Inst, Charlotte, NC USA

[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[3] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[4] Norris Cotton Canc Ctr, Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Lebanon, NH USA

[5] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[6] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[7] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] City Hope Comprehens Canc Ctr, Duarte, CA USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[10] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[12] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[13] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[14] Bristol Myers Squibb Co, Princeton, NJ USA

[15] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.5010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

5010

引用

页数：1